Therapeutic siRNAs and nonviral systems for their delivery

Molecular Biology

Volumn 46, Issue 3, 2012, Pages 335-348

  Glebova, K V ^a   Marakhonov, A V ^a   Baranova, A V ^a,b   Skoblov, M Yu ^a  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

RNA interference; siRNA; siRNA delivery

Indexed keywords

EID: 84862330212     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893312020069     Document Type: Article

References (144)

1. Areas of Interest for RNA Therapeutics. http://www. siRNA. com/partnering-opportunities/interest. html.
2. Kim E. J., Shim G., Kim K., Kwon I. C., Oh Y. K., Shim C. K. 2009. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J. Gene Med. 11, 791-803.
3. Braasch D. A., Paroo Z., Constantinescu A., Ren G., Oz O. K., Mason R. P., Corey D. R. 2004. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14, 1139-1143.
4. Hall A. H., Wan J., Shaughnessy E. E., Ramsay Sh. B., Alexander K. A. 2004. RNA interference using boranophosphate siRNAs: Structure-activity relationships. Nucleic Acids Res. 32, 5991-6000.
5. Chiu Y. L., Rana T. M. 2003. siRNA function in RNAi: A chemical modification analysis. RNA. 9, 1034-1048.
6. Layzer J. M., McCaffrey A. P., Tanner A. K., Huang Z., Kay M. A., Sullenger B. A. 2004. In vivo activity of nuclease-resistant siRNAs. RNA. 10, 766-771.
7. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R. K., Racie T., Rajeev K. G., Röhl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H. P. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432, 173-178.
8. de Paula D., Bentley M. V., Mahato R. I. 2007. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 13, 431-456.
9. Behlke M. A. 2008. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 18, 305-319.
10. Ikeda Y., Taira K. 2006. Ligand-targeted delivery of therapeutic siRNA. Pharm. Res. 23, 1631-1640.
11. Bumcrot D., Manoharan M., Koteliansky V., Sah D. W. 2006. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711-719.
12. Amarzguioui M., Holen T., Babaie E., Prydz H. 2003. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595.
13. Shaw B. R., Moussa L., Sharaf M., Cheek M., Dobrikov M. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators. 2008. Nucleic Acids Symp. Ser. (Oxford). 52, 655-656.
14. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G. J., Giese K., Kaufmann J. 2003. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716.
15. Prakash T. P., Allerson C. R., Dande P., Vickers T. A., Sioufi N., Jarres R., Baher B. F., Swayze E. E., Griffey R. H., Bhar B. 2005. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-4253.
16. Judge A. D., Bola G., Lee A. C., MacLachlan I. 2006. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505.
17. Elmen J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Orum H., Koch T., Wahlestedt C. 2005. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439-447.
18. Laursen M. M., Pakula M. B., Gao S., Fluiter K., Mook O. R., Baas F., Langklaer N., Wengel S. L., Wengel J., Kjems J., Bramsen J. B. 2010. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosyst. 6, 862-870.
19. Obika S., Nanbu D., Hari Y., Andoh J., Morio K., Doi T., Imanishi T. 1998. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O, 4′-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401-5404.
20. Koshkin A. A., Singh S. K., Nielsen P., Rajwanshi V. K., Kumar R., Meldgaard M., Olsen C. E., Wengel J. 1998. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine, and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron. 54, 3607-3630.
21. Singh S. K., Nielsen P., Koshkin A. A., Wengel J. 1998. LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition. J. Chem. Commun. 4, 455-456.
22. Fluiter K., Mook O. R., Baas F. 2009. The therapeutic potential of LNA-modified siRNAs: Reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol. Biol. 487, 189-203.
23. Mook O. R., Baas F., de Wissel M. B., Fluiter K. 2007. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 6, 833-843.
24. UsiRNA Technology. http://www. marinabio. com/usinra-technology.
25. Moschos S. A, Jones S. W., Perry M. M., Williams A. E., Erjefalt J. S., Turner J. J., Barnes P. J., Sproat B. S., Gait M. J., Lindsay M. A. 2007. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 18, 1450-1459.
26. Muratovska A., Eccles M. R. 2004. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558, 63-68.
27. Futaki S. 2002. Arginine-rich peptides: Potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.
28. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., Sugiura Y. 2001. Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836-5840.
29. Melikov K., Chernomordik L. V. 2005. Arginine-rich cell penetrating peptides: From endosomal uptake to nuclear delivery. Cell. Mol. Life Sci. 62, 2739-2749.
30. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. 1996. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271, 18188-18193.
31. Pooga M., Hallbrink M., Zorko M., Langel U. 1998. Cell penetration by transportan. FASEB J. 12, 67-77.
32. Cohen J. L., Almutairi A., Cohen J. A., Bernstein M., Brody S. L., Schuster D. P., Fréchet J. M. 2008. Enhanced cell penetration of acid-degradable particles functionalized with cell-penetrating peptides. Bioconjug. Chem. 19, 876-881.
33. Deshayes S., Morris M. C., Divita G., Heitz F. 2005. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62, 1839-1849.
34. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., Harashima H., Sugiura Y. 2001. Stearylated arginine-rich peptides: A new class of transfection systems. Bioconjug. Chem. 12, 1005-1011.
35. Console S., Marty C., Garcia-Echeverria C., Schwendener R., Ballmer-Hofer K. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278, 35109-35114.
36. Zhang W., Smith S. O. 2005. Mechanism of penetration of Antp(43-58) into membrane bilayers. Biochemistry. 44, 10110-10118.
37. Futaki S., Nakase I., Tadokoro A., Takeuchi T., Jones A. T. 2007. Arginine-rich peptides and their internalization mechanisms. Biochem. Soc. Trans. 35, 784-787.
38. Nakase I., Niwa M., Takeuchi T., Sonomura K., Kawabata N., Koike Y., Takehashi M., Tanaka S., Ueda K., Simpson J. C., Jones A. T., Sugiura Y., Futaki S. 2004. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011-1022.
39. Nakase I., Tadokoro A., Kawabata N., Takeuchi T., Katoh H., Hiramoto K., Negishi M., Nomizu M., Sugiura Y., Futaki S. 2007. Interaction of argininerich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry. 46, 492-501.
40. Tokatlian T., Segura T. 2010. siRNA applications in nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 305-315.
41. Eguchi A., Meade B. R., Chang Y. C., Fredrickson C. T., Willert K., Puri N., Dowdy S. F. 2009. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nature Biotechnol. 27, 567-571.
42. Kim W. J., Christensen L. V., Jo S., Yockman J. W., Jeong J. H., Kim Y. H., Kim S. W. 2006. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14, 343-350.
43. Kumar L. D., Clarke A. R. 2007. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv. Drug Deliv. Rev. 59, 87-100.
44. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., Kataoka K. 2005. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127, 1624-1625.
45. Rozema D. B., Lewis D. L., Wakefield D. H., Wong S. C., Klein J. J., Roesch P. L., Bertin S. L., Reppen T. W., Chu Q., Blokhin A. V., Hagstrom J. E., Wolff J. A. 2007. Dynamic Polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 104, 12982-12987.
46. Wolfrum C., Shi S., Jayaprakash K. N., Jayaraman M., Wang G., Pandey R. K., Rajeev K. G., Nakayama T., Charrise K., Ndungo E. M., Zimmermann T., Koteliansky V., Manoharan M., Stoffel M. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnol. 25, 1149-1157.
47. Nishina K., Unno T., Uno Y., Kubodera T., Kanouchi T., Miz U. S. Awa H., Yokota T. 2008. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734-740.
48. Dharmacon RNAi Technologies. http://www. dharmacon. com/PopUpTemplate. aspx?id=1033.
49. Check Hayen E. 2008. Thousands of proteins affected by miRNAs. Nature. 454, 562.
50. Hung C. F., Lu K. C., Cheng T. L., Wu R. H., Huang L. Y., Teng C. F., Chanq W. T. 2006. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochem. Biophys. Res. Commun. 346, 707-720.
51. Alsheddi T., Vasin L., Meduri R., Randhawa M., Glazko G., Baranova A. 2008. siRNAs with high specificity to the target: A systematic design by CRM algorithm. Mol. Biol. (Moscow). 42, 163-171.
52. Tilesi F., Fradiani P., Socci V., Willems D., Ascenzioni F. 2009. Design and validation of siRNAs and shRNAs. Curr. Opin. Mol. Ther. 11, 156-164.
53. Baranova A., Bode J., Manyam G., Emelianenko M. 2011. An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design. BMC Res. Notes. 27, 168.
54. Birmingham A., Anderson E. M., Reynolds A., Ilsley-Tyree D., Leake D., Fedorov Y., Baskerville S., Maksimova E., Robinson K., Karpilow J., Marshall W. S., Khvorova A. 2006. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nature Methods. 3, 199-204.
55. Weitzer S., Martinez J. 2007. hClp1: A novel kinase revitalizes RNA metabolism. Cell Cycle. 6, 2133-2137.
56. Chen P. Y., Weinmann L., Gaidatzis D., Pei Y., Zavolan M., Tuschl T., Meister G. 2008. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA. 14, 263-274.
57. Off-Target Effects: Disturbing the Silence of RNA interference (RNAi). http://www. dharmacon. com/uploadedFiles/Home/Support-Center/Technical-Reviews/off-target-tech-review. pdf.
58. Kirchhoff F. 2008. Silencing HIV-1 in vivo. Cell. 134, 566-568.
59. Leng Q., Woodle M. C., Lu P. Y., Mixson A. J. 2009. Advances in systemic siRNA delivery. Drugs Future. 34, 721.
60. Li W., Szoka Jr. F. C. 2007. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24, 438-449.
61. Juliano R., Bauman J., Kang H., Ming X. 2009. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6, 686-695.
62. Scherphof G. L. 1991. In vivo behavior of liposomes: Interactions with the mononuclear phagocyte system and implications for drug targeting. In: Handbook of Experimental Pharmacology. Ed. Juliano R. L. Berlin: Springer, vol. 100, pp. 285-300.
63. Shim M. S., Kwon Y. J. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277, 4814-4827.
64. Jang S. H., Wientjes M. G., Lu D., Au J. L. 2003. Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-13350.
65. Cho-Rock J., Yoo J., Jang Y. J., Kim S., Chu I.-S., Yeom Y. I., Choi J. Y., Im D.-S. 2006. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 43, 1042-1052.
66. Juliano R., Alam M. R., Dixit V., Kang H. 2008. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 4158-4171.
67. Khalil I. A., Kogure K., Akita H., Harashima H. 2006. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58, 32-45.
68. Rejman J., Oberle V., Zuhorn I. S., Hoekstra D. 2004. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159-169.
69. Spagnou S., Miller A. D., Keller M. 2004. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry. 43, 13348-13356.
70. Tong A. W., Jay C. M., Senzer N., Maples P. B., Nemunaitis J. 2009. Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr. Gene Ther. 9, 45-60.
71. Zelphati O., Uyechi L. S., Barron L. G., Szoka Jr. F. C. 1998. Effect of serum components on the physicochemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta. 1390, 119-133.
72. Li S., Huang L. 1997. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4, 891-900.
73. Liu F., Qi H., Huang L., Liu D. 1997. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther. 4, 517-523.
74. Oja C. D., Semple S. C., Chonn A., Cullis P. 1996. Influence of dose on liposome clearance: Critical role of blood proteins. Biochim. Biophys. Acta. 1281, 31-37.
75. Semple S. C., Chonn A., Cullis P. 1996. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 35, 2521-2525.
76. David S., Pitard B., Benoît J. P., Passirani C. 2010. Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62, 100-114.
77. Ogris M., Wagner E. 2002. Targeting tumors with nonviral gene delivery systems. Drug Discov. Today. 7, 479-485.
78. Gref R., Minamitake Y., Peracchia M. T., Trubetskoy V., Torchilin V., Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science. 263, 1600-1603.
79. Veronses F. M., Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discovery Today. 10, 1451-1458.
80. Guo J., Fisher K. A., Darcy R., Cryan J. F., O'Driscoll C. 2010. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol. Biosys. 6, 1143-1161.
81. Ishida T., Kiwada H. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56-62.
82. Kim E. J., Shim G., Kim K., Kwon I. C., Oh Y. K., Shim C. K. 2009. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J. Gene Med. 11, 791-803.
83. Wang Y., Li Z., Han Y., Liang L. H., Ji A. 2010. Nanoparticle-based delivery system for application of siRNA in vivo. Curr. Drug Metab. 11, 182-196.
84. Jiang G., Park K., Kim J., Kim K. S., Hahn S. K. 2009. Target-specific intracellular delivery of siRNA/PEIHA complex by receptor mediated endocytosis. Mol. Pharm. 6, 727-737.
85. de Martimprey H., Vauthier C., Malvy C., Couvreur P. 2009. Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA. Eur. J. Pharm. Biopharm. 71, 490-504.
86. Kircheis R., Schuller S., Brunner S., Ogris M., Heider K. H., Zauner W., Wagner E. J. 1999. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. Gene Med. 1, 111-120.
87. Pitard B., Oudrhiri N., Lambert O., Vivien E., Masson C., Wetzer B., Hauchecorne M., Scherman D., Rigaud J. L., Vigneron J. P., Lehn J. M., Lehn P. 2001. Sterically stabilized BGTC-based lipoplexes: Structural features and gene transfection into the mouse airways in vivo. Gene Med. 3, 478-487.
88. Pack D. W., Hoffman A. S., Pun S., Stayton P. S. 2005. Design and development of polymers for gene delivery. Nature Rev. Drug Discovery. 4, 581-593.
89. Howard K. A., Rahbek U. L., Liu X., Damgaard C. K., Glud S. Z., Andersen M. O., Hovgaard M. B., Schmitz A., Nyengaard J. R., Besenbacher F., Kjems J. 2006. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484.
90. Zhang X., Shan P., Jiang D., Noble P. W., Abraham N. G., Kappas A., Lee P. J. 2004. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279, 10677-10684.
91. Bitko V., Musiyenko A., Shulyayeva O., Barik S. 2005. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50-55.
92. de Vry J., Martínez-Martínez P., Losen M., Temel Y., Steckler T., Steinbusch H. W., de Baets M. H., Prickaerts J. 2010. In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog. Neurobiol. 92, 227-44.
93. Makimura H., Mizuno T. M., Mastaitis J. W., Agami R., Mobbs C. V. 2002. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci. 3, 18.
94. Thakker D. R., Natt F., Hüsken D., Maier R., Müller M., van der Putten H., Hoyer D., Cryan J. F. 2004. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl. Acad. Sci. U. S. A. 101, 17270-17275.
95. Thakker D. R., Hüsken D., van der Putten H., Maier R., Hoyer D., Cryan J. F. 2005. siRNA-mediated knock-down of the serotonin transporter in the adult mouse brain. Mol. Psychiatry. 10, 782-789, 714.
96. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., Barclay J., Natt F. J., Martin P., Bevan, S., Fox A., Ganju P., Wishart W., Hall J. 2004. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49.
97. Emerson M. V., Lauer A. K. 2007. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs. 21, 245-257.
98. Tompkins S. M., Lo C. Y., Tumpey T. M., Epstein S. L. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U. S. A. 101, 8682-8686.
99. Chae S. S., Paik J. H., Furneaux H., Hla T. 2004. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114, 1082-1089.
100. Song E., Zhu P., Lee S. K., Chowdhury D., Kussman S., Dykxhoorn D. M., Feng Y., Palliser D., Weiner D. B., Shankar P., Marasco W. A., Lieberman J. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709-717.
101. Wu S. Y., McMillan N. A. 2009. Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639-652.
102. Palliser D., Chowdhury D., Wang Q. Y., Lee S. J., Bronson R. T., Knipe D. M., Lieberman J. 2006. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 439, 89-94.
103. Azuma M., Ritprajak P., Hashiguchi M. 2010. Topical application of siRNA targeting cutaneous dendritic cells in allergic skin disease. Methods Mol. Biol. 623, 373-381.
104. Takanashi M., Oikawa K., Sudo K., Tanaka M., Fujita K., Ishikawa A., Nakae S., Kaspar R. L., Matsuzaki M., Kudo M., Kuroda M. 2009. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther. 16, 982-989.
105. Manjunath N., Dykxhoorn D. M. 2010. Advances in synthetic siRNA delivery. Discov. Med. 9, 418-430.
106. Pirollo K. F., Rait A., Zhou Q., Hwang S. H., Dagata J. A., Zon G., Hogrefe R. I., Palchik G., Chang E. H. 2007. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938-2943.
107. Peer D., Zhu P., Carman C. V., Lieberman J., Shimaoka M. 2007. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. U. S. A. 104, 4095-4100.
108. Sato A., Takagi M., Shimamoto A., Kawakami S., Hashida M. 2007. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials. 28, 1434-1442.
109. Hu-Lieskovan S., Heidel J. D., Bartlett D. W., Davis M. E., Triche T. J. 2005. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992.
110. Schiffelers R. M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P. Y., Scaria P. V., Woodle M. C. 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
111. Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207.
112. Greish K. 2010. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 624, 25-37.
113. Zhou J., Rossi J. J. 2010. Aptamer-targeted cell-specific RNA interference. Silence. 1, 4.
114. Gold L., Polisky B., Uhlenbeck O., Yarus M. 1995. Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64, 763-797.
115. Dassie J. P., Liu X. Y., Thomas G. S., Whitaker R. M., Thiel K. W., Stockdale K. R., Meyerholz D. K., McCaffrey A. P., McNamara J. O., Giangrande P. H. 2009. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotechnol. 27, 839-849.
116. McNamara J. O., Andrechek E. R., Wang Y., Viles K. D., Rempel R. E., Gilboa E., Sullenger B. A., Giangrande P. H. 2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnol. 24, 1005-1015.
117. Peer D., Park E. J., Morishita Y., Carman C. V., Shimaoka M. 2008. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 319, 627-630.
118. Zhang Y., Zhang Y. F., Bryant J., Charles A., Boado R. J., Pardridge W. M. 2004. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10, 3667-3677.
119. Watanabe T., Umehara T., Yasui F., Nakagawa S., Yano J., Ohgi T., Sonoke S., Satoh K., Inoue K., Yoshiba M., Kohara M. 2007. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J. Hepatol. 47, 744-750.
120. Chen Y., Sen J., Bathula S. R., Yang Q., Fittipaldi R., Huang L. 2009. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 6, 696-705.
121. Senior J. H., Trimble K. R., Maskiewicz R. 1991. Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta. 1070, 173-179.
122. Sakurai F., Nishioka T., Saito H., Baba T., Okuda A., Matsumoto O., Taga T., Yamashita F., Takakura Y., Hashida M. 2001. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid. Gene Ther. 8, 677-686.
123. Oyewumi M. O., Yokel R. A., Jay M., Coakley T., Mumper R. J. 2004. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control Release. 95, 613-626.
124. Richardson S. C., Kolbe H. V., Duncan R. 1999. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution, and ability to complex and protect DNA. Int. J. Pharm. 178, 231-243.
125. Akhtar S., Benter I. 2007. Toxicogenomics of nonviral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182.
126. Hollins A. J., Omidi Y., Benter I. F., Akhtar S. 2007. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target. 15, 83-88.
127. Omidi Y., Hollins A. J., Drayton R. M., Akhtar S. 2005. Polypropylenimine dendrimer-induced gene expression changes: The effect of complexation with DNA, dendrimer generation and cell type. J. Drug Target. 13, 431-443.
128. Omidi Y., Hollins A. J., Benboubetra M., Drayton R., Benter I. F., Akhtar S. 2003. Toxicogenomics of nonviral vectors for gene therapy: A microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target. 6, 311-323.
129. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411, 494-498.
130. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., Hartmann G. 2005. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270.
131. Sioud M., Sørensen D. R. 2003. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220-1225.
132. Judge A. D., Sood V., Shaw J. R., Fang D., McClintock K., MacLachlan I. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457-462.
133. Kariko K., Bhuyan P., Capodici J., Weissman D. 2004. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545-6549.
134. Marques J. T., Williams B. R. G. 2005. Activation of the mammalian immune system by siRNAs. Nature Biotechnol. 23, 1399-1405.
135. Robbins M., Judge A., MacLachlan I. 2009. siRNA and innate immunity. Oligonucleotides. 19, 89-102.
136. Ma Z., Li J., He F., Wilson A., Pitt B., Li S. 2005. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755-759.
137. Ge Q., Filip L., Bai A., Nguyen T., Eisen H. N., Chen J. 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U. S. A. 101, 8676-8681.
138. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R. K., Racie T., Rajeev K. G., Röhl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H. P. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432, 173-178.
139. Zimmermann T. S., Lee A. C., Akinc A., Bramlage B., Bumcrot D., Fedoruk, M. N., Harborth J., Heyes J. A., Jeffs L. B., John M., Judge A. D., Lam K., McClintock K., Nechev L. V., Palmer L. R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A. J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H. P., MacLachlan I. 2006. RNAi-mediated gene silencing in non-human primates. Nature. 441, 111-114.
140. Gantier M. P., Tong S., Behlke M. A., Irving A. T., Lappas M., Nilsson U. W., Latz E., McMillan N. A., Williams B. R. 2010. Rational design of immunostimulatory siRNAs. Mol. Ther. 18, 785-795.
141. Furset G., Sioud M. 2007. Design of bifunctional siRNAs: Combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem. Biophys. Res. Commun. 352, 642-649.
142. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S. S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., Schmidt A., Anz D., Bscheider M., Schwerd T., Berking C., Bourquin C., Kalinke U., Kremmer E., Kato H., Akira S., Meyers R., Häcker G., Neuenhahn M., Busch D., Ruland J., Rothenfusser S., Prinz M., Hornung V., Endres S., Tüting T., Hartmann G. 2008. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Med. 14, 1256-1263.
143. Liu S., Shibata A., Ueno S., Huang Y., Wang Y., Li Y. 2006. Translocation of positively charged copoly(Lys/Tyr) across phospholipid membranes. Biochem. Biophys. Res. Commun. 339, 761-768.
144. Cedervall T., Lynch I., Lindman S., Berggard T., Thulin E., Nilsson H., Dawson K. A., Linse S. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 104, 2050-2055.